Asthma and COPD Drugs Market size is anticipated to surpass USD 30 billion by the end of 2035,growing at a CAGR of 10% during the forecast period i.e., 2023-2035. In the year 2022, the industry size of asthma and COPD drugs was USD 11 billion. The market growth is due to the increasing prevalence of respiratory diseases.
The industry includes a variety of drugs, including bronchodilators, corticosteroids, combination therapies, and monoclonal antibodies. Furthermore, there have been surging investments in drugs, and therapy by competitors for the cure of diseases in order to have a competitive advantage.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~ 10% |
|
Base Year Market Size (2022) |
~ USD 11 Billion |
|
Forecast Year Market Size (2035) |
~ USD 30 Billion |
|
Regional Scope |
|
End User (Asthma Patients, COPD Patients)
The COPD patients segment in the asthma and COPD drugs market is expected to witness around 60% growth rate through 2035. The growth of the segment can be accredited to the increasing prevalence of smoking.
Smoking is a major cause of COPD. While smoking rates have been declining in many parts of the world, there are still significant numbers of smokers, particularly in low- and middle-income countries. This is estimated to contribute to the increasing prevalence of COPD and drive demand for COPD drugs.
Distribution Channel (General Pharmacies, Online Retailers, Hospital Pharmacies)
The hospital pharmacies segment is estimated to gain the largest market share in the year 2035. Respiratory diseases such as asthma and COPD can require hospitalization, particularly in severe cases. The increasing prevalence of these conditions is likely to lead to an increase in hospitalizations, which is likely to drive demand for asthma and COPD drugs in hospital pharmacies.
According to a study of 2020, hospitalizations for asthma increased during the COVID-19 pandemic in several countries, across the globe. The study found that hospitalizations for asthma increased by 30-70% in these countries during the pandemic.
Our in-depth analysis of the global market includes the following segments:
|
Distribution Channel |
|
|
End User |
|
|
Route of Administration |
|
North American Market Forecast
The asthma and COPD drugs market in the North America region, amongst all the other regions, are projected to hold the largest share between 2023 and 2035. The growing healthcare infrastructure in the North American region is able to provide the required treatment to the patients.
In addition, the governments and private insurance companies in North America generally provide favorable reimbursement policies for drugs dispensed through pharmacies and hospitals.
APAC Market Statistics
The Asia Pacific asthma and COPD drugs market is poised to register substantial growth rate during the forecast period. The aging population in the Asia Pacific region is growing rapidly, which is expected to lead to an increase in the number of people with respiratory diseases, particularly COPD.
Several governments in the region are taking initiatives to improve healthcare access and outcomes, including for respiratory diseases. For instance, the Chinese government launched the "Healthy China 2030" initiative, which aims to reduce the burden of chronic diseases, including respiratory diseases.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?